Adolor maintained by Merrill at neutral

Adolor Corp. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating following the company's announcement that the FDA confimed the primary endpoint of Adolor's GI2 is acceptable in the ongoing phase III post-operative ileus trial. Merrill believes this point may not be clinically meaningful, however. Adolor shares Wednesday were up $0.80, or 8.51%, at $10.20 on volume of 1,000,203 shares versus the three-month running average of 580,414 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.